Quick Answer
Immuneering Corp reported Total Revenue of $0.00 for the year ending 2023.
- Immuneering Corp showed a decrease of -100.0% in Total Revenue from 2022 to 2023.
- This data is from Immuneering Corp's annual report (Form 10-K), filed with the SEC on March 1, 2024.
- XBRL data for this metric is available from 2020 to 2023 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $480.8 thousand | Q3 2020: $682.6 thousand | Q1 2021: $748.2 thousand | Q2 2021: $660.0 thousand | Q3 2021: $482.1 thousand | Q1 2022: $183.7 thousand | Q2 2022: $94.4 thousand | Q3 2022: $38.4 thousand | Q1 2023: $0.00 | Q2 2023: $0.00 | Q3 2023: $0.00.
- Over the full 4 years of available data (2020 to 2023), Immuneering Corp's Total Revenue has declined by 100.0%.
- Historical annual values: Fiscal year 2023: $0.00 | Fiscal year 2022: $317.0 thousand | Fiscal year 2021: $2.08 million | Fiscal year 2020: $2.31 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: